Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study

Autor(es)

Costa, Alana C. ^{[1, 2]} ; Joaquim, Helena P. G. ^{[1, 2]} ; Forlenza, V, Orestes ; Gattaz, Wagner F. ^{[3, 4]} ; Talib, Leda L. ^{[3, 4]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Dept & Inst Psiquiatria, Lab Neurociencias LIM 27, Fac Med, Rua Dr Ovidio Pires de Campos 785, 3 Andar, BR-05403010 Sao Paulo - Brazil

^[2] Conselho Nacl Dev Cientif & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBioN, Sao Paulo - Brazil

^[3] Forlenza, Orestes, V, Univ Sao Paulo, Dept & Inst Psiquiatria, Lab Neurociencias LIM 27, Fac Med, Rua Dr Ovidio Pires de Campos 785, 3 Andar, BR-05403010 Sao Paulo - Brazil

^[4] Forlenza, Orestes, V, Conselho Nacl Dev Cientif & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria INBioN, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE; v. 270, n. 4, p. 483-488, JUN 2020.
• Citações Web of Science: 0

Resumo

The metabolomic profile of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) may suggest potential diagnostic biomarkers and provide information on the pathophysiology of dementia. Our aim was to quantify plasmatic metabolites of AD patients, MCI and controls. We investigated the metabolomic profile-using the AbsoluteIDQ (R) p180 assay-of 79 older adults with primary cognitive impairment (34 AD and 20 MCI) and 25 healthy elders (controls). A cluster analysis revealed that a combination C12-DC, C12 and PCaaC26:0 could differentiate the patients according to diagnostic. Future studies should combine metabolomic profiles with other biomarkers to identify diagnostic groups. (AU)

• Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
• Beneficiário: Wagner Farid Gattaz
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 14/20913-3 - Determinação de fosfolípides plasmáticos nas doenças neuropsiquiátricas
• Beneficiário: Alana Caroline Costa
• Modalidade de apoio: Bolsas no Brasil - Mestrado